Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LipoKnoxa™ Human CPT1A shRNA AAV Particle (Silencing)
Cat. No.:
V0126XX307
Species:
Human
Target Gene:
CPT1A
Vector System:
AAV
Modulation Type:
Silencing (shRNA)
SPECIFIC INQUIRY
Add to basket
| Sub Cat. No. | AAV Serotype | Tissue Tropism | TargetSeq | Region | Inquiry |
|---|---|---|---|---|---|
| V0126XX307-1 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-2 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-3 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-4 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-5 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-6 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-7 | AAV3 | Lung; Liver; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-8 | AAV3 | Lung; Liver; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-9 | AAV3 | Lung; Liver; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-10 | AAV4 | CNS; Retina; Heart; Lung; Kidney | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-11 | AAV4 | CNS; Retina; Heart; Lung; Kidney | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-12 | AAV4 | CNS; Retina; Heart; Lung; Kidney | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-13 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-14 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-15 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-16 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-17 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-18 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-19 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-20 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-21 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-22 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-23 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-24 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-25 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | GCGTTCTTCGTGACGTTAGAT | CDS | Inquiry |
| V0126XX307-26 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | CGATGTTACGACAGGTGGTTT | CDS | Inquiry |
| V0126XX307-27 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | CGTAGCCTTTGGTAAAGGAAT | CDS | Inquiry |
| V0126XX307-28 | Other | Inquiry |
Product Overview
Description:
LipoKnoxa™ Human CPT1A shRNA AAV Particle (Silencing) targets the liver isoform of CPT1A, essential for mitochondrial fatty acid oxidation. This silencing tool is built on an advanced RNAi platform supporting both U6 and miR30-based shRNA systems. Multiple AAV serotypes are provided to optimize in vivo delivery. Each preparation undergoes comprehensive quality control, covering functional titer, sequence identity, and sterility, ensuring that results are scientifically sound.
Production Cell Line:
HEK293
AAV ITR:
AAV2 ITR
Promoter:
U6; CMV; EF1α; CAG; UBC
Product Availability:
Produced Upon Order
Specification
Titer Test:
qPCR
Insert Verification:
The sequence identity and genomic integrity of all preparations were successfully confirmed via sequencing and PCR validation.
Sterility Test:
Stringent QC assays have verified the sterility of this product lot, ensuring it is free of all detectable microbial contaminants.
Mycoplasma Test:
Confirmed free of mycoplasma contamination via high-sensitivity QC assays; this product lot has successfully passed the production safety protocols.
Other QC:
Tailored supplementary testing and transduction performance assays are available to evaluate gene silencing at the molecular level. We provide comprehensive in vitro and in vivo assessments to elucidate the impact of shRNA-targeted editing on gene expression profiles and downstream biological phenotypes.
Storage:
To maintain optimal viral potency and structural integrity, it is essential to store the vector at -80°C immediately following its receipt.
Stability:
Long-term storage at -80°C ensures product integrity for up to 24 months. For immediate experimental use, the thawed viral preparations are refrigerated at 4°C, maintaining robust performance for a period of 2–3 weeks.
Shipping Condition:
Shipped on dry ice. Product integrity is guaranteed through temperature-controlled logistics for all viral vector types.
Handling Notes:
To prevent titer loss caused by repeated freeze-thaw cycles, we recommend aliquoting the virus into single-use volumes upon receipt. Use low-protein-binding microcentrifuge tubes and store under specified conditions. Strict adherence to biosafety protocols is required; perform all handling within a designated biosafety cabinet.
Intended Use:
This product is intended for research use only and is not for use in diagnosis or therapeutic applications.
Product Disclaimer:
All products undergo stringent quality control; however, no warranty is provided for performance in specific applications, given the diversity of experimental variables. The user is ultimately responsible for ensuring proper storage, handling, and adherence to all local laws, biosafety standards, and safety regulations throughout the use of the product.
Target Profile
Gene Name:
CPT1A
Full Name:
Carnitine palmitoyltransferase 1A
Gene Symbol:
CPT1; CPT I; CPT1-L; CPTI-L; L-CPT1
Gene ID:
1374
RefSeq ID-1:
NP_001027017.1
RefSeq ID-2:
NM_001031847.3
Summary:
CPT1A is the rate-limiting enzyme for mitochondrial fat burning (beta-oxidation). Located on the outer mitochondrial membrane, it facilitates the transport of long-chain fatty acids into the mitochondria for energy production. A lack of CPT1A activity prevents the body from utilizing stored fat effectively. The balance between ACACA (fat building) and CPT1A (fat burning) is a critical axis in the study of weight management and metabolic health.